SIGHT SCIENCES INC. - COMMON STOCK

Sight Sciences Announces the Release of its First Sustainability Report

10 Jun 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

28 May 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

28 May 2024 07:30:01 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

07 May 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

02 May 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

29 Apr 2024 07:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

18 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

10 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

02 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

26 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance

07 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

22 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

14 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

23 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

08 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

28 Dec 2023 08:15:21 By Nasdaq GlobeNewswire

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

18 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

08 Dec 2023 07:05:00 By Nasdaq GlobeNewswire

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

07 Nov 2023 15:05:01 By Nasdaq GlobeNewswire

Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

24 Oct 2023 15:05:00 By Nasdaq GlobeNewswire